The Azista Bhutan Healthcare Limited (ABHL) is a Joint Venture Company of Azista Industries Pvt. Ltd., Hyderabad, India www.azistaindustries.com and Druk Holding and Investments Ltd., RGoB, Bhutan www.dhi.bt. And now they have ambition to enter European Union with center operation in Slovakia.
ABHL's pharmaceutical as a clean industry is known for not generating any toxic and hazardous effluents. The state of the art technology that would be deployed for this project will ensure that the plant does not emit hazardous materials into the atmosphere. ABHL is a project that is in compliance with the country’s development philosophy of Gross National Happiness.
Vision
To become a global healthcare organization and to be recognized as domestic and internationally integrated healthcare and pharmaceutical company through Innovation, Quality and Competence. To become the leading pharmaceutical player in the industry by assuring high quality standards and cost effective products at all times. We want to mark our presence in the society by creating a portfolio of low cost medicines available to all.
Mission
To uphold our social responsibilities of delivering the highest standard healthcare services to all segments of society without compromising on our core values of integrity, good ethics and commitment. To become a globally acclaimed pharmaceutical company through development and introduction of wide portfolio of Pharmaceutical.
Azista Bhutan Healthcare
ABHL is setting up a full – fledged pharmaceutical plant at Motanga Industrial Park, Samdrup Jongkhar to manufacture, package and distribute wide range of prescription medicines under the brand Azista Bhutan. Such facility would be first of its kind in Bhutan that would manufacture, package and distribute allopathic drugs.
Given the rising demand for pharmaceutical products both in the local and international markets, and the fact that Bhutan has been importing all allopathic drugs from outside, DHI took such initiative not only to curb import but also to promote brand Bhutan in a global market through export of locally manufactured quality pharmaceutical products. Once operational, the company would be manufacturing, packaging and distributing 99 types of products under 17 major therapies. Besides meeting domestic demand for pharmaceutical products, the plant will export to India and abroad. We are glad that they chose Slovakia and Indian Chamber of Commerce to start negotiations with SUKL (Slovak Institute for Drug Control)
Contact
P.B.C. OBULA REDDY.
AZISTA BHUTAN HEALTHCARE LIMITED
CHIEF EXECUTIVE OFFICER
